Quan Dong Nguyen, Eduardo Buchele Rodrigues, Michel Eid Farah

Retinal Pharmacotherapy

.

• Gebundenes Buch

Produktbeschreibung

Retinal Pharmacotherapy is the first comprehensive book devoted to pharmacologic agents and their rationale and mechanisms of action in selected retinal and uveitic diseases. Drs. Quan Dong Nguyen, Eduardo Buchele Rodrigues, Michel Eid Farah, and William F. Mieler lead an international team of expert contributors to present up-to-date knowledge of new drugs on the market, the science behind the drugs, evidence of how the drugs work, and the reasons why they are effective or not. This user-friendly, all-in-one reference provides you with easy access to practical information on the effective and appropriate use of pharmacologic agents in the management of retinal diseases.
04
Retinal Toxicity of Systemic and Topical Medications
Section 3: Retinal Diseases Amenable to Pharmacotherapy
17 Non-neovascular Age-Related Macular Degeneration
18 Neovascular Age-Related Macular Degeneration
19 Diabetic Retinopathy and Diabetic Macular Edema
20 Retinal Vein Occlusion
21 Retinal Detachment and Proliferative Vitreoretinopathy
22 Posterior Uveitis
23 Choroidal Neovascularization Secondary to Inflammation, Infection, and Myopia
24 Ocular Infection: Endophthalmitis
25 Retinopathy of Prematurity
26 Idiopathic Macular Telangiectasia
27 Neovascular Glaucoma
28 Retinal Hereditary and Degenerative / Dystrophic Diseases (non-AMD)
Section 4: Drugs and Mechanisms in Retinal Diseases
29 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Retinal Diseases
30 Corticosteroids: Triamcinolone, Dexamethasone, Fluocinolone, and Others
31 Anecortave Acetate
32 Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab
33 Therapeutic Monoclonal Antibo

Produktdetails

• Verlag: Saunders
• Seitenzahl: 408
• Erscheinungstermin: 18. August 2011
• Englisch
• Abmessung: 281mm x 222mm x 23mm
• Gewicht: 1458g
• ISBN-13: 9781437706031
• ISBN-10: 1437706037
• Artikelnr.: 32278357

Inhaltsangabe

1 Evolving Knowledge in Pharmacologic Treatments
Section 1: Basic Sciences in Retina
2 Retinal Anatomy and Pathology
3 Retinal Biochemistry, Physiology and Cell Biology
4 Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors
5 Ocular Immunity and Inflammation
6 Complement Activation and Inhibition in Retinal Disease
7 Genetics of Retinal Disease
Section 2: Animal Models and Routes for Retinal Drug Delivery
8 Vitamins and Supplements for Age-Related Macular Degeneration
9 Ocular Pharmacokinetic, Drug Bioavailability and Intraocular Drug Delivery Systems
0 Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections and Vitrectomy
11 Routes for Drug Delivery: Topical, Transscleral, Suprachoroidal, and Intravitreal Gas-Phase Nanoparticles
12 Routes for Drug Delivery: Sustained-Release Devices
13 Microspheres and Nanotechnology for Drug Delivery
14 Thermo-sensitive Hydrogels
15 Retina and Ocular Toxicity to Ocular Application of Drugs
16 Retinal Toxicity of Systemic and Topical Medications
Section 3: Retinal Diseases Amenable to Pharmacotherapy
17 Non-neovascular Age-Related Macular Degeneration
18 Neovascular Age-Related Macular Degeneration
19 Diabetic Retinopathy and Diabetic Macular Edema
20 Retinal Vein Occlusion
21 Retinal Detachment and Proliferative Vitreoretinopathy
22 Posterior Uveitis
23 Choroidal Neovascularization Secondary to Inflammation, Infection, and Myopia
24 Ocular Infection: Endophthalmitis
25 Retinopathy of Prematurity
26 Idiopathic Macular Telangiectasia
27 Neovascular Glaucoma
28 Retinal Hereditary and Degenerative / Dystrophic Diseases (non-AMD)
Section 4: Drugs and Mechanisms in Retinal Diseases
29 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Retinal Diseases
30 Corticosteroids: Triamcinolone, Dexamethasone, Fluocinolone, and Others
31 Anecortave Acetate
32 Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab
33 Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab
34 Pathophysiology of Vascular Endothelial Growth Factor and Other Angiogenic Molecules
35 Biologic Therapies: Infliximab, Adalimumab, Etanercept, Daclizumab, and Others
36 Immunomodulatory Therapy in Uveitis
37 Fusion Proteins: VEGF-Trap
38 Aptamers and Intramers: Pegaptanib
39 Protein Kinase C Inhibitor: Ruboxistaurin
40 Small-Interference RNA Technology: SIRNA 027, Bevasiranib, and REDD14NP
41 Ocular Gene Therapy
42 Neuroprotection and Retinal Diseases
43 Photosensitizers and Photodynamic Therapy: Verteporfin
44 Chemotherapy for Malignant Intraocular Tumors
45 Antibiotics
Section 5: Pharmacotherapy and Surgery
46 Rheotherapy (Rheopheresis; Therapeutical Apheresis)
47 Enzymatic Vitrectomy and Pharmacologic Vitreodynamics
48 The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy
49 Epimacular and External Radiotherapy
50 Current Status of Human Retinal Pigment Epithelial Transplantation
Section 6: The Last Words
51 Off-Label Drugs and the Impact of the Food and Drug Administration in the Treatment of Retinal Disease
52 Value-Based Medicine and Pharmacoeconomics
53 Future Perspectives: Agents on the Horizon